180 Life Sciences Corp (ATNF)
1.94
-0.06
(-3.00%)
USD |
NASDAQ |
May 03, 15:18
180 Life Sciences SG&A Expense (Quarterly): 1.489M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.489M |
September 30, 2023 | 2.433M |
June 30, 2023 | 2.762M |
March 31, 2023 | 4.009M |
December 31, 2022 | 5.054M |
September 30, 2022 | 3.419M |
June 30, 2022 | 4.018M |
March 31, 2022 | 2.974M |
December 31, 2021 | 2.490M |
September 30, 2021 | 3.602M |
Date | Value |
---|---|
June 30, 2021 | 3.019M |
March 31, 2021 | 2.581M |
December 31, 2020 | 1.557M |
September 30, 2020 | 0.2315M |
June 30, 2020 | 0.5031M |
March 31, 2020 | 1.063M |
December 31, 2019 | 18.07M |
September 30, 2019 | 0.2257M |
June 30, 2019 | 0.2964M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.2257M
Minimum
Sep 2019
18.07M
Maximum
Dec 2019
3.147M
Average
2.581M
Median
Mar 2021
SG&A Expense (Quarterly) Benchmarks
Seelos Therapeutics Inc | 2.746M |
Altimmune Inc | 4.332M |
GT Biopharma Inc | 1.811M |
Outlook Therapeutics Inc | 5.794M |
MAIA Biotechnology Inc | 2.660M |